- Home
- CGC vs EOLS Comparison
CGC vs EOLS Comparison
Compare CGC & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGC
- EOLS
- Stock Information
- Founded
- CGC N/A
- EOLS 2012
- Country
- CGC Canada
- EOLS United States
- Employees
- CGC N/A
- EOLS N/A
- Industry
- CGC Pharmaceuticals and Biotechnology
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- CGC Health Care
- EOLS Health Care
- Exchange
- CGC Nasdaq
- EOLS Nasdaq
- Market Cap
- CGC 431.7M
- EOLS 406.9M
- IPO Year
- CGC N/A
- EOLS 2018
- Fundamental
- Price
- CGC $1.37
- EOLS $6.50
- Analyst Decision
- CGC Hold
- EOLS Strong Buy
- Analyst Count
- CGC 1
- EOLS 4
- Target Price
- CGC N/A
- EOLS $21.25
- AVG Volume (30 Days)
- CGC 23.8M
- EOLS 1.0M
- Earning Date
- CGC 11-07-2025
- EOLS 11-05-2025
- Dividend Yield
- CGC N/A
- EOLS N/A
- EPS Growth
- CGC N/A
- EOLS N/A
- EPS
- CGC N/A
- EOLS N/A
- Revenue
- CGC $201,572,742.00
- EOLS $277,941,000.00
- Revenue This Year
- CGC $13.24
- EOLS $13.68
- Revenue Next Year
- CGC $3.68
- EOLS $27.96
- P/E Ratio
- CGC N/A
- EOLS N/A
- Revenue Growth
- CGC N/A
- EOLS 17.15
- 52 Week Low
- CGC $0.77
- EOLS $5.71
- 52 Week High
- CGC $5.80
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- CGC 48.83
- EOLS 44.82
- Support Level
- CGC $1.32
- EOLS $6.08
- Resistance Level
- CGC $1.46
- EOLS $6.36
- Average True Range (ATR)
- CGC 0.11
- EOLS 0.22
- MACD
- CGC -0.00
- EOLS 0.04
- Stochastic Oscillator
- CGC 23.53
- EOLS 71.96
About CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.